Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
322
resultados
Última actualización
25/08/2026 [07:57:00]
Resultados 175 a 200 de 322
Resumen de: CN122410031A
本发明提供了美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用，属于生物医药技术领域。本发明发现GluN2A蛋白是小细胞肺癌不良预后及靶向干预的重要分子标志物。另外，本发明发现美金刚、其衍生物或药用盐能够以剂量依赖的方式显著抑制小细胞肺癌细胞的活力、克隆形成能力、DNA复制活性及迁移能力，并有效破坏3D肿瘤球体的形成、诱导肿瘤细胞死亡，显著减小了小细胞肺癌异种移植瘤的体积和重量。本发明提供的伴随诊断与靶向用药策略，克服了传统非选择性用药的盲目性，为现有小细胞肺癌的治疗提供了新的药物解决方案。
Resumen de: AU2025215582A1
The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.
Resumen de: US20260202374A1
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Resumen de: WO2026151983A1
Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.
Resumen de: WO2026151932A1
The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.
Resumen de: WO2026151876A1
Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.
Resumen de: WO2026150914A1
This pharmaceutical composition for use in the treatment of patients with diseases associated decreased ATP levels comprises the DNA or mRNA of at least one molecule selected from the group consisting of PI3Kα, IGFBP1, EIF2S2, OCIAD2, MANF, and GAPDHS.
Resumen de: WO2026148492A1
Provided are a biological target and associated therapeutic strategies for treating or preventing neurodegenerative diseases characterized by pathological α-synuclein (α-syn) fibril transmission.
Resumen de: WO2026151828A1
Provided are methods of isolating or extracting human mitochondrial tryptophan-rich sensory protein (HsTSPOl). The methods include contacting the H.sTSPOl with an effective amount of at least one Native Cell Membrane Nanoparticle (NCMN) polymer and recovering the TSPO. Compositions containing TPSO encapsulated in a particle formed by the NCNM polymer are also provided. A protoporphyrin derivative compound, methods of producing bilindigin or derivatives thereof, and methods of screening compounds that modulate TSPO activity are also provided.
Resumen de: US20260201046A1
Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.
Resumen de: US20260199318A1
Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasonmal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
Resumen de: US20260199341A1
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Resumen de: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Resumen de: US20260199509A1
Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.
Resumen de: AU2024388350A1
The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Resumen de: WO2026149125A1
Provided are a nanobody against γ-aminobutyric acid type B receptor, and a preparation method therefor and the use thereof. The nanobody can specifically recognize and bind to the γ-aminobutyric acid type B receptor, exhibits a good affinity therefor, and can be used in the preparation of a product for diagnosing, preventing or treating diseases or conditions associated with the γ-aminobutyric acid type B receptor, or for detecting the presence or level of the γ-aminobutyric acid type B receptor in a sample.
Resumen de: US20260202397A1
0000 The present invention describes a method for assessing the potency of a pharmaceutical product assumed to be effective in treating a disorder, preferably a genetic disorder or a non-genetic disorder, wherein the disorder results in an impaired functionality of a physiological bodily function of a subject having the disorder, wherein the method comprises: (i) incubating an engineered tissue with the pharmaceutical product, wherein the engineered tissue is or has been modified to be representative for the disorder; (ii) determining at least one physical parameter of the engineered tissue resulting from step (i), wherein the physical parameter is a measure of the functionality of the physiological bodily function, and (iii) determining whether a value of the at least one physical parameter determined in step (ii) meets a predetermined threshold of said physical parameter, which determines whether the pharmaceutical product has potency, wherein, if said value of the at least one physical parameter exceeds the predetermined threshold, potency of the pharmaceutical product is indicated for treating the disorder by at least partially restoring the functionality of the physiological bodily function.
Resumen de: US20260200988A1
Polypeptides capable of specifically recognizing and binding to the neutral amino acid transporter ASCT1/SLC1A4, while not binding to the related neutral amino acid transporter ASCT2/SLC1A5. Also, both in vitro and in vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.
Resumen de: US20260201015A1
0000 Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods for use of the polypeptides in detecting binding of the target and correlating binding to the target with a disease state.
Resumen de: US20260202406A1
0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.
Resumen de: US20260202422A1
The invention relates to a method of treatment for early onset preeclampsia in a pregnant subject, including determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The invention further relates to the combined measurement of sFlt-1 and PlGF, The invention relates further to a kit for carrying out the method of the invention, including detection reagents for determining the level sFlt-1 or fragment(s) thereof, and optionally for determining the level of at least one additional biomarker, in a sample from a subject.
Resumen de: US20260201473A1
0000 Biomarkers that can be used for the detection or diagnosis of disease states, preferably cancer (e.g., triple negative breast cancer (TNBC)) disease states, to the prediction of disease prognosis and/or a treatment outcome, to the identification of a treatment regimen for cancer (e.g., TNBC), and/or to indicate the responsiveness to the treatment regimen for cancer (e.g., TNBC) in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining cancer (e.g., TNBC) disease states and/or identification of treatment regimens for the cancer (e.g., TNBC) disease states.
Resumen de: US20260201023A1
0000 Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: AU2024418168A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Nº publicación: JP2026524000A 16/07/2026
Solicitante:
デューポイントセラピューティクス，インコーポレイテッド
Resumen de: WO2025014769A1
The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.
BOPI
Sede Electrónica
